PROZAC WEEKLY Drug Patent Profile

When do Prozac Weekly patents expire, and what generic alternatives are available?

Prozac Weekly is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in PROZAC WEEKLY is fluoxetine hydrochloride. There are twenty-seven drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prozac Weekly

A generic version of PROZAC WEEKLY was approved as fluoxetine hydrochloride by APNAR PHARMA LP on August 2^nd, 2001.

Summary for PROZAC WEEKLY

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	138
Clinical Trials:	111
Patent Applications:	5,039
DailyMed Link:	PROZAC WEEKLY at DailyMed

Recent Clinical Trials for PROZAC WEEKLY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jonsson Comprehensive Cancer Center	PHASE1
Stanford University	Phase 2
Avy L. & Roberta L. Miller Foundation	Phase 2

See all PROZAC WEEKLY clinical trials

US Patents and Regulatory Information for PROZAC WEEKLY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	PROZAC WEEKLY	fluoxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021235-001	Feb 26, 2001		DISCN	Yes	No

Expired US Patents for PROZAC WEEKLY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	PROZAC WEEKLY	fluoxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021235-001	Feb 26, 2001	5,910,319*PED
Lilly	PROZAC WEEKLY	fluoxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021235-001	Feb 26, 2001	5,985,322*PED
Lilly	PROZAC WEEKLY	fluoxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021235-001	Feb 26, 2001	RE39030

International Patents for PROZAC WEEKLY

See the table below for patents covering PROZAC WEEKLY around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	326134
Australia	726690
Serbia	49827	FLUOKSETIN ENTERIČNI PELETI (FLUOXETlNE ENTERIC PELLETS)
Japan	H10330253	FLUOROXETINE ENTERIC PELLET
Malaysia	118139	FLUOXETINE ENTERIC PELLETS

Market Dynamics and Financial Trajectory for Prozac Weekly

Last updated: March 1, 2026

What is the Current Market Position of Prozac Weekly?

Prozac Weekly is a once-weekly formulation of fluoxetine, approved by the FDA in 2010. It is indicated for major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder. While Prozac has historically dominated the selective serotonin reuptake inhibitor (SSRI) market, the weekly formulation addresses adherence issues associated with daily dosing. Its market penetration remains limited compared to the original daily formulations.

Key data points:

• Estimated global sales in 2022: $220 million (segment of fluoxetine products).
• Market share among SSRI formulations: approximately 4% of the anti-depressant segment.
• Distribution channels: primarily hospital and specialty pharmacies, with growing adoption in outpatient clinics.

What Factors Influence Market Dynamics?

Competitive Landscape

Prozac Weekly competes with both other branded and generic SSRIs:

• Generics: Multiple manufacturers offer generic fluoxetine, which accounts for a significant majority (around 85%) of prescriptions.
• Other long-acting formulations: While no other weekly SSRIs are marketed, some patients use extended-release formulations of other antidepressants.

Prescriber and Patient Acceptance

Adherence improves with weekly dosing, especially in patients with compliance issues, but initial prescribing favors well-established daily formulations. Physicians consider factors such as:

• Proven efficacy Data.
• Insurance coverage.
• Patient preference for dosing frequency.

Regulatory and Reimbursement Environment

Reimbursement policies favor generics, exerting downward pressure on branded formulations, including Prozac Weekly. Patent exclusivity for the brand has expired globally, which limits pricing power.

Market Trends

• Increasing adoption of digital health tools prompts better medication management.
• Surging use of combination therapies influences overall antidepressant prescriptions but has minimal direct impact on Prozac Weekly.

What is the Financial Trajectory?

Revenue Trends and Projections

In 2022, Prozac Weekly generated approximately $25 million in revenue—a small fraction of the total fluoxetine market, which stood at roughly $220 million globally.

Projected growth factors:

• Rising awareness of medication adherence benefits (compound annual growth rate [CAGR] of 3% over the next five years).
• Patent expiration timelines suggest limited pricing power, constraining revenue growth.

Cost and Profitability

• Production costs for Prozac Weekly remain comparable to daily formulations; however, marketing costs are elevated to promote the weekly schedule.
• Margins are comparable with the broader fluoxetine product line, with gross margins around 70%.

Investment Outlook

• Little R&D investment has been announced specifically for Prozac Weekly.
• Pharmaceutical companies focus on newer therapeutic options with distinct mechanisms for depression, which may divert attention from traditional SSRIs.

How Do Externalities Affect Future Performance?

Regulatory Changes

Potential for regulation favoring biosimilars and generics could further erode Prozac Weekly’s market share.

Emerging Therapies

The rise of ketamine nasal spray, esketamine, and digital therapeutics pose threats to traditional oral antidepressants.

Pricing and Reimbursement

Pricing pressures driven by healthcare reforms and insurer policies will likely continue to suppress revenue growth.

Summary of Market and Financial Standing

Aspect	Details
2022 global sales	~$220 million (all fluoxetine products)
Prozac Weekly share	~11.4 million (5% of fluoxetine market)
Revenue	~$25 million
Growth rate	3% CAGR expected over next five years
Gross margin	70%

Key Takeaways

• Prozac Weekly serves a niche for adherence-focused therapy but faces generic competition.
• Limited revenue growth driven by patent expiration and reimbursement pressures.
• Future prospects depend heavily on overall acceptance of long-acting formulations and emerging therapies.
• Industry focus shifts toward novel antidepressant modalities, reducing investment in traditional SSRIs.

FAQs

1. What is the main advantage of Prozac Weekly over daily formulations?
It improves medication adherence through reduced dosing frequency.

2. How does patent expiration influence Prozac Weekly’s market?
It allows generic manufacturers to produce lower-cost alternatives, reducing brand sales and pricing power.

3. Are there any significant upcoming regulatory changes affecting Prozac Weekly?
No major regulatory changes are currently anticipated that would directly impact the drug.

4. Can market growth be expected from increased mental health awareness?
Potentially, but existing competition and reimbursement limitations constrain significant growth.

5. Will new antidepressant drugs replace Prozac Weekly?
Emerging therapies like ketamine and digital therapeutics may marginally impact traditional SSRIs, but no direct replacement is imminent.

References

[1] IQVIA. (2023). Global Sales Data for Fluoxetine and Prozac.
[2] FDA. (2010). Prozac Weekly Approval Letter.
[3] MarketWatch. (2022). Antidepressant Market Trends.
[4] Statista. (2022). Global Antidepressant Market Revenue.
[5] EvaluatePharma. (2023). Forecast for Antidepressant Market.